<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512448106</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512448106</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Rossi</surname><given-names>Silvia</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512448106">1</xref>
<xref ref-type="aff" rid="aff2-1352458512448106">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Motta</surname><given-names>Caterina</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512448106">1</xref>
<xref ref-type="aff" rid="aff2-1352458512448106">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Studer</surname><given-names>Valeria</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512448106">1</xref>
<xref ref-type="aff" rid="aff2-1352458512448106">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Monteleone</surname><given-names>Fabrizia</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512448106">1</xref>
<xref ref-type="aff" rid="aff2-1352458512448106">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>De Chiara</surname><given-names>Valentina</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512448106">1</xref>
<xref ref-type="aff" rid="aff2-1352458512448106">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Buttari</surname><given-names>Fabio</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512448106">1</xref>
<xref ref-type="aff" rid="aff2-1352458512448106">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Barbieri</surname><given-names>Francesca</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512448106">1</xref>
<xref ref-type="aff" rid="aff2-1352458512448106">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bernardi</surname><given-names>Giorgio</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512448106">1</xref>
<xref ref-type="aff" rid="aff2-1352458512448106">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Battistini</surname><given-names>Luca</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512448106">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cutter</surname><given-names>Gary</given-names></name>
<xref ref-type="aff" rid="aff3-1352458512448106">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Stüve</surname><given-names>Olaf</given-names></name>
<xref ref-type="aff" rid="aff4-1352458512448106">4</xref>
<xref ref-type="aff" rid="aff5-1352458512448106">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Salvetti</surname><given-names>Marco</given-names></name>
<xref ref-type="aff" rid="aff6-1352458512448106">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Centonze</surname><given-names>Diego</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512448106">1</xref>
<xref ref-type="aff" rid="aff2-1352458512448106">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512448106"><label>1</label>Clinica Neurologica, Università Tor Vergata, Italy.</aff>
<aff id="aff2-1352458512448106"><label>2</label>Centro Europeo per la Ricerca sul Cervello/ Fondazione Santa Lucia, Italy.</aff>
<aff id="aff3-1352458512448106"><label>3</label>Department of Biostatiscs, University of Alabama, USA.</aff>
<aff id="aff4-1352458512448106"><label>4</label>Department of Neurology, Dallas Veterans Affairs Medical Center, USA.</aff>
<aff id="aff5-1352458512448106"><label>5</label>Department of Neurology, University of Texas Southwestern Medical Center at Dallas, USA.</aff>
<aff id="aff6-1352458512448106"><label>6</label>Centre for Experimental Neurologica Therapies, S. Andrea Hospital, Italy.</aff>
<author-notes>
<corresp id="corresp1-1352458512448106">Diego Centonze, Clinica Neurologica, Dipartimento di Neuroscienze, Università Tor Vergata, Via Montpellier 1, 00133 Rome, Italy. Email: <email>centonze@uniroma2.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>59</fpage>
<lpage>68</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>1</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>4</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>4</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1352458512448106">
<title>Background:</title>
<p>Multiple sclerosis (MS) patients discontinuing natalizumab treatment are at risk of disease reactivation. No clinical or surrogate parameters exist to identify patients at risk of post-natalizumab MS reactivation.</p>
</sec>
<sec id="section2-1352458512448106">
<title>Objective:</title>
<p>To determine the role of natalizumab-induced lymphocytosis and of Akt polymorphisms in disease reactivation after natalizumab discontinuation.</p>
</sec>
<sec id="section3-1352458512448106">
<title>Methods:</title>
<p>Peripheral leukocyte count and composition were monitored in 93 MS patients during natalizumab treatment, and in 56 of these subjects who discontinued the treatment. Genetic variants of the anti-apoptotic protein Akt were determined in all subjects because natalizumab modulates the apoptotic pathway and lymphocyte survival is regulated by the apoptotic cascade.</p>
</sec>
<sec id="section4-1352458512448106">
<title>Results:</title>
<p>Natalizumab-induced peripheral lymphocytosis protected from post-natalizumab MS reactivation. Subjects who relapsed or had magnetic resonance imaging (MRI) worsening after treatment cessation, in fact, had milder peripheral lymphocyte increases during the treatment, largely caused by less marked T cell increase. Furthermore, subjects carrying a variant of the gene coding for Akt associated with reduced anti-apoptotic efficiency (rs2498804T) had lower lymphocytosis and higher risk of disease reactivation.</p>
</sec>
<sec id="section5-1352458512448106">
<title>Conclusion:</title>
<p>This study identified one functionally meaningful genetic variant within the Akt signaling pathway that is associated with both lymphocyte count and composition alterations during natalizumab treatment, and with the risk of disease reactivation after natalizumab discontinuation.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Apoptosis</kwd>
<kwd>CIRIS</kwd>
<kwd>rebound</kwd>
<kwd>relapse</kwd>
<kwd>lymphocytosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section6-1352458512448106" sec-type="intro">
<title>Introduction</title>
<p>Natalizumab provides rapid control over disease activity in patients with aggressive breakthrough disease.<sup><xref ref-type="bibr" rid="bibr1-1352458512448106">1</xref>,<xref ref-type="bibr" rid="bibr2-1352458512448106">2</xref></sup> Unfortunately, long-term use of natalizumab is associated with an elevated risk of progressive multifocal leukoencephalopathy (PML), which is caused by local reactivation of JC virus.<sup><xref ref-type="bibr" rid="bibr3-1352458512448106">3</xref><xref ref-type="bibr" rid="bibr4-1352458512448106"/><xref ref-type="bibr" rid="bibr5-1352458512448106"/>–<xref ref-type="bibr" rid="bibr6-1352458512448106">6</xref></sup> Recent seroepidemiological surveys indicated that around 50% of patients are seropositive for JC virus<sup><xref ref-type="bibr" rid="bibr7-1352458512448106">7</xref></sup> and thus potentially at risk for PML if treated with natalizumab.</p>
<p>In order to mitigate the risk of developing PML, limiting exposure to natalizumab would be a reasonable strategy. However, discontinuing natalizumab appears to lead to disease reactivation. Reactivation or even rebound of disease has been reported to occur within six months after stopping natalizumab, especially in patients who presented high disease activity the year before treatment initiation.<sup><xref ref-type="bibr" rid="bibr8-1352458512448106">8</xref><xref ref-type="bibr" rid="bibr9-1352458512448106"/><xref ref-type="bibr" rid="bibr10-1352458512448106"/><xref ref-type="bibr" rid="bibr11-1352458512448106"/><xref ref-type="bibr" rid="bibr12-1352458512448106"/><xref ref-type="bibr" rid="bibr13-1352458512448106"/>–<xref ref-type="bibr" rid="bibr14-1352458512448106">14</xref></sup> Since most patients prescribed with natalizumab in clinical practice have an aggressive MS course, the risk of reactivation or rebound after treatment discontinuation is a clinically important issue, and it is therefore highly desirable to identify those subjects at risk of disease progression after natalizumab treatment in order to develop strategies to minimize this risk.</p>
<p>Natalizumab prevents penetration into the central nervous system (CNS) of autoreactive B and T lymphocytes,<sup><xref ref-type="bibr" rid="bibr2-1352458512448106">2</xref></sup> and their survival in the periphery might be involved in disease reoccurrence after natalizumab cessation. Lymphocyte survival is regulated by complex mechanisms involving the apoptotic cascade,<sup><xref ref-type="bibr" rid="bibr15-1352458512448106">15</xref><xref ref-type="bibr" rid="bibr16-1352458512448106"/>–<xref ref-type="bibr" rid="bibr17-1352458512448106">17</xref></sup> and we postulated that individual differences in the efficiency of lymphocyte survival mechanisms could explain why some patients undergo MS reactivation or even rebound after natalizumab discontinuation. In this respect, specific single nucleotide polymorphisms (SNPs) in genes regulating the apoptosis cascade result in significantly different biological effects of the respective proteins in humans,<sup><xref ref-type="bibr" rid="bibr18-1352458512448106">18</xref><xref ref-type="bibr" rid="bibr19-1352458512448106"/><xref ref-type="bibr" rid="bibr20-1352458512448106"/><xref ref-type="bibr" rid="bibr21-1352458512448106"/><xref ref-type="bibr" rid="bibr22-1352458512448106"/><xref ref-type="bibr" rid="bibr23-1352458512448106"/>–<xref ref-type="bibr" rid="bibr24-1352458512448106">24</xref></sup> providing a potentially important option to address our hypothesis.</p>
</sec>
<sec id="section7-1352458512448106" sec-type="methods">
<title>Patients and methods</title>
<p>This study complied with the principles of the Declaration of Helsinki, and was approved by the Ethical Committee of the Policlinico Università Tor Vergata in Rome. All of the subjects gave their written informed consent to the study.</p>
<sec id="section8-1352458512448106">
<title>Subjects</title>
<p>We followed 100 consecutive patients with relapsing–remitting MS<sup><xref ref-type="bibr" rid="bibr25-1352458512448106">25</xref></sup> who started treatment with natalizumab (Tysabri<sup>®</sup>; Biogen Idec Inc.; 300 mg IV every four weeks). Only subjects who were fully responsive to natalizumab were taken into account for the analyses (<italic>n</italic>=93). The responsiveness to natalizumab was defined as: no occurrence of clinical relapses and detection of active scans at magnetic resonance imaging (MRI) for the entire duration of the treatment. We excluded patients who relapsed under natalizumab to avoid possible confounding effects caused by peripheral immune activation or of corticosteroid treatment on peripheral blood cell count and composition.</p>
<p>Demographic and clinical information were derived from medical records. All subjects had active forms of relapsing–remitting MS. Eighty-seven percent of patients had two or more relapses the year before natalizumab initiation, despite treatment with high-dose interferon (IFN) beta-1a (Rebif 44, three times a week by subcutaneous injections), IFN beta-1b (Betaferon, alternate days by subcutaneous injections), glatiramer acetate (GA, Copaxone, daily subcutaneous injections). Three patients also had a clinical history of mitoxantrone treatment (3–6 infusions, 39–110 mg in total), from 24–41 months before natalizumab initiation. Patients on immunomodulatory therapy before initiation of natalizumab treatment had a minimum washout period of one month. Normal blood counts were required before initiation of natalizumab treatment.</p>
<p>Annualized relapse rate (ARR) was 2.39±0.8 prior to natalizumab treatment initiation. None of the patients was treated with corticosteroids or any other immunoactive drugs during natalizumab therapy.</p>
<p>Fifty-six subjects discontinued natalizumab after 12–28 infusions to reduce the risk of PML, and received IFN beta-1b (19 patients) or GA (37 patients) starting four weeks after the last dose of natalizumab, for at least six months or until a clinical relapse occurred. These patients were divided into a stable and an active group according to clinical and radiological parameters (stable: no relapses and no MRI reactivation, <italic>n</italic>=17; active: relapse and/or MRI reactivation, <italic>n</italic>=39). The subjects who discontinued natalizumab were also divided into a low lymphocyte group (L-LY group, <italic>n</italic>=29) and a high lymphocyte group (H-LY group, <italic>n</italic>=27) according to the grade of natalizumab-induced lymphocytosis. Patients’ demographic, clinical and treatment information are shown in <xref ref-type="table" rid="table1-1352458512448106">Table 1</xref>, <xref ref-type="table" rid="table2-1352458512448106">2</xref> and <xref ref-type="table" rid="table3-1352458512448106">3</xref>.</p>
<table-wrap id="table1-1352458512448106" position="float">
<label>Table 1.</label>
<caption>
<p>Patients’ demographic, clinical, and treatment information.</p>
</caption>
<graphic alternate-form-of="table1-1352458512448106" xlink:href="10.1177_1352458512448106-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<tbody>
<tr>
<td>Subject (<italic>n</italic>)</td>
<td>93</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>32/61</td>
</tr>
<tr>
<td>Age (years)</td>
<td>37.5 ± 8.1</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>8.9 ± 4.1</td>
</tr>
<tr>
<td>T0 EDSS</td>
<td>3.1 ± 1.1</td>
</tr>
<tr>
<td>Natalizumab therapy (months)</td>
<td>16.2 ± 4.2</td>
</tr>
<tr>
<td>Treatment before natalizumab therapy (IFNβ1b/IFNβ1a/GA/none)</td>
<td>29/33/23/8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458512448106">
<p>EDSS: Expanded Disability Status Scale; F: female; GA: glatiramer acetate; IFN: interferon; M: male.</p>
</fn>
<fn id="table-fn2-1352458512448106">
<p>Data are mean ± standard deviation (SD) unless otherwise specified.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1352458512448106" position="float">
<label>Table 2.</label>
<caption>
<p>Demographic, clinical, and treatment information for stable and active patients.</p>
</caption>
<graphic alternate-form-of="table2-1352458512448106" xlink:href="10.1177_1352458512448106-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Stable</th>
<th align="left">Active</th>
<th align="left"><italic>p</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject (<italic>n</italic>)</td>
<td>17</td>
<td>39</td>
<td/>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>8/9</td>
<td>14/25</td>
<td>0.55</td>
</tr>
<tr>
<td>Age (years)</td>
<td>38.7 ± 9.8</td>
<td>37.1 ± 7.2</td>
<td>0.47</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>9.1 ± 4.9</td>
<td>8.9 ± 3.7</td>
<td>0.91</td>
</tr>
<tr>
<td>ARR before natalizumab</td>
<td>1.9 ± 0.8</td>
<td>2.4 ± 0.8</td>
<td>0.09</td>
</tr>
<tr>
<td>Treatment before natalizumab therapy (IFNβ1b/IFNβ1a/GA/none)</td>
<td>6/5/5/1</td>
<td>13/14/9/3</td>
<td/>
</tr>
<tr>
<td>Treatment after natalizumab therapy (IFNβ1b / GA)</td>
<td>4/13</td>
<td>15/24</td>
<td>0.36</td>
</tr>
<tr>
<td>P0 EDSS</td>
<td>2.9 ± 1.1</td>
<td>3.1 ± 0.9</td>
<td>0.31</td>
</tr>
<tr>
<td>T0 peripheral lymphocytes (count/ml)</td>
<td>1928 ± 597</td>
<td>2086 ± 789</td>
<td>0.46</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1352458512448106">
<p>ARR: annualized relapse rate; EDSS: Expanded Disability Status Scale; F: female; GA: glatiramer acetate; IFN: interferon; M: male.</p>
</fn>
<fn id="table-fn4-1352458512448106">
<p>Data are mean ± standard deviation (SD) unless otherwise specified.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-1352458512448106" position="float">
<label>Table 3.</label>
<caption>
<p>Demographic, clinical, and treatment information for H-LY and L-LY patients.</p>
</caption>
<graphic alternate-form-of="table3-1352458512448106" xlink:href="10.1177_1352458512448106-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">H-LY</th>
<th align="left">L-LY</th>
<th align="left"><italic>p</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject (<italic>n</italic>)</td>
<td>27</td>
<td>29</td>
<td/>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>12/15</td>
<td>8/21</td>
<td>0.26</td>
</tr>
<tr>
<td>Age (years)</td>
<td>37.5 ± 8.3</td>
<td>37.6 ± 7.9</td>
<td>0.96</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>8.7 ± 3.9</td>
<td>9.2 ± 4.2</td>
<td>0.60</td>
</tr>
<tr>
<td>ARR before natalizumab</td>
<td>2.1 ± 0.8</td>
<td>2.3 ± 0.9</td>
<td>0.48</td>
</tr>
<tr>
<td>Treatment before natalizumab therapy (IFNβ1b/IFNβ1a/GA/none)</td>
<td>12/6/6/3</td>
<td>7/13/8/1</td>
<td/>
</tr>
<tr>
<td>T0 EDSS</td>
<td>3.1 ± 1.1</td>
<td>3.3 ± 1.1</td>
<td>0.34</td>
</tr>
<tr>
<td>T0 peripheral lymphocytes (count/ml)</td>
<td>1913 ± 476</td>
<td>2154 ± 904</td>
<td>0.22</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1352458512448106">
<p>ARR: annualized relapse rate; EDSS: Expanded Disability Status Scale; F: female; GA: glatiramer acetate; H-LY : high lymphocyte group; IFN: interferon; L-LY: low lymphocyte group; M: male.</p>
</fn>
<fn id="table-fn6-1352458512448106">
<p>Data are mean ± standard deviation (SD) unless otherwise specified.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Other subgroups of subjects were analyzed as follows:</p>
<list id="list1-1352458512448106" list-type="order">
<list-item><p>Sixty-seven subjects consented to DNA extraction for SNPs of Akt gene analysis and were classified, according to rs2498804 polymorphism, in GG (<italic>n</italic>=29) and GT/TT (<italic>n</italic>=38) groups. Forty-two of them discontinued natalizumab.</p></list-item>
<list-item><p>Sixty-one subjects provided a count of lymphocyte subpopulations. Forty-five of them discontinued natalizumab.</p></list-item>
</list>
</sec>
<sec id="section9-1352458512448106">
<title>Study procedures</title>
<p>Venipuncture for blood cell DNA extraction and periodic clinical assessments were performed at the MS Center of Policlinico Università Tor Vergata by MS specialist neurologists. Blood cell counts were obtained during routine blood investigations, performed 24–48 hours before natalizumab infusions at baseline (T0) and monthly thereafter, at each time point until the twelfth infusion (T1–T12). Counts of different cell populations, obtained by flow cytometry at T0 and T6, were available in a subgroup of subjects (<italic>n</italic>=61). For those patients who discontinued natalizumab, blood withdrawals were performed also four weeks after the last infusion (P0) and, monthly, for six months (P1–P6) or until natalizumab therapy was resumed.</p>
<p>The Expanded Disability Status Scale (EDSS), a 10-point disease severity score derived from nine ratings for individual neurological domains,<sup><xref ref-type="bibr" rid="bibr26-1352458512448106">26</xref></sup> was used to assess disability. Relapses, defined as the development of new or recurrent neurological symptoms not associated with fever or infection and lasting at least 24 hours, were confirmed when an increase of at least one point in one functional system was recorded. Assessment of disability and confirmation of relapses were performed by a neurologist who was unaware of the patient’s clinical details and laboratory data.</p>
<p>Cerebral and spinal MRI scans were performed at T0 and T12 and, for subjects who discontinued natalizumab, at P0 and P6.</p>
</sec>
<sec id="section10-1352458512448106">
<title>MRI acquisition and analysis</title>
<p>MRI scans (1.5 Tesla) consisted of dual-echo proton density, FLAIR, T2-weighted spin-echo images (T2-WI) and pre-contrast and post-contrast T1-weighted spin-echo images (T1-WI). All images were acquired in the axial orientation with 3 mm thick contiguous slices. A new Gd+ (0.2 ml/kg e.v.) lesion was defined as a typical area of hyperintense signal on postcontrast T1-WI. A new or newly enlarging lesion on T2-WI was defined as a rounded or oval lesion arising from an area previously considered as normal-appearing brain tissue and/or showing an identifiable increase in size from a previously stable-appearing lesion. The mean number of new combined active lesions (CALs), as the number of enhancing lesions plus the number of new or newly enlarging non-enhancing lesions was also determined. An active scan was defined as showing any new, enlarging, or recurrent lesion(s) on postcontrast T1- and T2-WI. Analyses were performed by a neuroradiologist who was unaware of the patient’s clinical details and laboratory data.</p>
</sec>
<sec id="section11-1352458512448106">
<title>Determination of SNPs in the apoptotic cascade</title>
<p>The MassARRAY Assay Design 3.1 software was used to design a single 20-multiplex reaction in which six SNPs of Akt, a key molecule in the apoptotic cascade, (rs3803300, rs1130214, rs3730358, rs1130233, rs2494732, rs2498804) were included. Genotyping was performed using iPLEX Gold technology<sup><xref ref-type="bibr" rid="bibr27-1352458512448106">27</xref></sup> and MassARRAY high-throughput DNA analysis with Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (Sequenom, Inc., San Diego, California, USA), according to the manufacturer’s instructions. The SNPs included showed a call rate higher than 95% with no significant departure from Hardy-Weinberg equilibrium.<sup><xref ref-type="bibr" rid="bibr28-1352458512448106">28</xref>,<xref ref-type="bibr" rid="bibr29-1352458512448106">29</xref></sup></p>
</sec>
<sec id="section12-1352458512448106">
<title>Statistical analysis</title>
<p>If not otherwise indicated, data are given as mean ± standard deviation (SD). A paired analysis of variance (ANOVA) was performed to analyze comparison during follow-up of natalizumab therapy. Comparisons between two groups of data were performed with the Student’s t test in the case of parametric samples, and with the Mann-Whitney test or Wilcoxon test in the case of nonparametric samples. The two-sided Fisher exact test was performed for contingency analysis. Odds ratios (ORs) or hazard ratios (HRs) along with the corresponding 95% confidence interval (CI) were provided. Survival curves were analyzed using the Log-rank (Mantel-Cox) Test and Gehan-Breslow-Wilcoxon Test. Patients who did not reach the endpoint were considered as censored data. Correlation analysis was performed by calculating Spearman coefficients. The level of significance was designated as <italic>p</italic>&lt;0.05 (two-tailed tests). A correction for multiple comparisons was applied.</p>
</sec>
</sec>
<sec id="section13-1352458512448106">
<title>Results</title>
<sec id="section14-1352458512448106">
<title>Lymphocyte count increases during natalizumab treatment</title>
<p>As in previous reports,<sup><xref ref-type="bibr" rid="bibr30-1352458512448106">30</xref><xref ref-type="bibr" rid="bibr31-1352458512448106"/>–<xref ref-type="bibr" rid="bibr32-1352458512448106">32</xref></sup> the number of total lymphocytes increased during natalizumab treatment within four weeks after the first infusion (T0: 2076.1±835.6/ml; T1: 3293±1132.8/ml; <italic>n</italic>=93, <italic>p</italic>&lt;0.0001). Lymphocyte numbers further increased until T6 (3891.4±1146.5/ml; <italic>p</italic>&lt;0.0001), and remained significantly higher at month 12 (3871.6±1016.7/ml; <italic>p</italic>&lt;0.0001) (<xref ref-type="fig" rid="fig1-1352458512448106">Figure 1A</xref>). Counts of different cell populations, available for a subgroup of subjects (<italic>n</italic>=61: 25 males, age 38.5±8.1 years), demonstrated that natalizumab increased the number of both B (CD19+) and T lymphocytes (CD3+CD4+ and CD3+CD8+), as well as of NK cells (CD56+). A disproportional increase of B lymphocytes over NK cells and T lymphocytes was found (<italic>p</italic>&lt;0.001, <italic>n</italic>=61) (<xref ref-type="fig" rid="fig1-1352458512448106">Figure 1B</xref>).</p>
<fig id="fig1-1352458512448106" position="float">
<label>Figure 1.</label>
<caption>
<p>Lymphocyte count increases during natalizumab treatment. (A.) The graph shows the percentage of lymphocyte increase during 12 consecutive natalizumab infusions. (B) Natalizumab induced a disproportional increase of B lymphocytes over NK cells and T lymphocytes. (C) The graphs show the percentage of increase respect to pre-natalizumab values or (D) the count of total lymphocytes after discontinuation of the therapy.</p>
<p>*<italic>p</italic>&lt;0.05.</p>
</caption>
<graphic xlink:href="10.1177_1352458512448106-fig1.tif"/>
</fig>
<p>Three months after natalizumab discontinuation, the absolute count of lymphocytes reverted to normal values (<italic>n</italic>=55, <italic>p</italic>&gt;0.05 respect T0), being reduced by 50% (<italic>n</italic>=55, <italic>p</italic>&lt;0.001) compared to T12 (<xref ref-type="fig" rid="fig1-1352458512448106">Figures 1C</xref> and <xref ref-type="fig" rid="fig1-1352458512448106">1D</xref>).</p>
</sec>
<sec id="section15-1352458512448106">
<title>Peripheral lymphocytosis protects from post-natalizumab MS reactivation</title>
<p>To see if peripheral lymphocytosis influenced post-natalizumab MS reactivation, patients discontinuing natalizumab were divided into a stable group (no relapses and no MRI reactivation, <italic>n</italic>=17) and an active group (relapse and/or MRI reactivation, <italic>n</italic>=39). As shown in <xref ref-type="table" rid="table2-1352458512448106">Table 2</xref>, the two groups did not differ in their demographic and clinical data, although a tendency towards higher ARR the year before natalizumab was found in the active group, in line with evidence of reactivation or rebound of disease reported to occur after natalizumab suspension in patients with high disease activity the year before initiating the treatment.<sup><xref ref-type="bibr" rid="bibr8-1352458512448106">8</xref>,<xref ref-type="bibr" rid="bibr9-1352458512448106">9</xref>,<xref ref-type="bibr" rid="bibr11-1352458512448106">11</xref></sup> Also the frequency of subjects receiving IFN beta-1b after natalizumab was higher, although not significantly, in the active group.</p>
<p>Surprisingly, the absolute number of circulating lymphocytes during natalizumab treatment was higher in the stable compared to the active group (T6: 4614.7±1122.4/ml versus 3751.8±1461.6/ml, <italic>n</italic>=56, <italic>p</italic>&lt;0.05). The relative increase of peripheral lymphocytes was higher in the stable group for all 12 months of observation, exceeding 200% of baseline values (<italic>n</italic>=56, <italic>p</italic>&lt;0.05) (<xref ref-type="fig" rid="fig2-1352458512448106">Figure 2A</xref>).</p>
<fig id="fig2-1352458512448106" position="float">
<label>Figure 2.</label>
<caption>
<p>Peripheral lymphocytosis protects from post-natalizumab multiple sclerosis (MS) reactivation. (A) The natalizumab-induced lymphocytosis was higher in the stable than in the active group. (B) The graph shows that the higher lymphocytosis in the stable group was secondary to the preferential increase of CD4+ and CD8+ T lymphocytes. (C) The natalizumab-induced lymphocytosis was higher in the stable than in the active group also after natalizumab discontinuation. (D) The number of subjects with MS reactivation was higher in the L-LY group with respect to the H-LY group. (E) The relapse-free rate and the time to relapse were higher in the H-LY group. (F) MRI parameters obtained from L-LY and H-LY groups at P6.</p>
<p>H-LY : high lymphocyte group; L-LY: low lymphocyte group; MRI: magnetic resonance imaging.</p>
<p>*<italic>p</italic>&lt;0.05.</p>
</caption>
<graphic xlink:href="10.1177_1352458512448106-fig2.tif"/>
</fig>
<p>A count of lymphocyte subpopulations was available for a subgroup of patients discontinuing natalizumab (<italic>n</italic>=45: 16 males, age 37.5±8.0 years). The analysis showed that higher lymphocytosis in the stable group was secondary to the preferential increase of CD4+ and CD8+ T lymphocytes (<italic>n</italic>=45, <italic>p</italic>&lt;0.01). B lymphocyte count was also higher in the stable group, but this increase did not reach statistical significance (<italic>n</italic>=45, <italic>p</italic>=0.09) (<xref ref-type="fig" rid="fig2-1352458512448106">Figure 2B</xref>).</p>
<p>Of note, in the stable group lymphocyte count remained beyond the baseline values still 6–7 months after the last infusion of natalizumab (T0: 1927±596.8/ml, P6: 2347.6±666.0/ml, <italic>n</italic>=17, <italic>p</italic>&lt;0.05), being significantly higher than the active group for each time point (<italic>p</italic>&lt;0.05) (<xref ref-type="fig" rid="fig2-1352458512448106">Figure 2C</xref>).</p>
<p>To further address the predictive value of lymphocytosis on post-natalizumab MS reactivation, we then divided MS subjects into a L-LY group (subjects who showed at T6 an increase of lymphocytes below 200% of baseline values) and a H-LY group (subjects who showed at T6 an increase of lymphocytes above 200%). The L-LY and H-LY groups did not differ in demographic and clinical variables before natalizumab therapy (<xref ref-type="table" rid="table3-1352458512448106">Table 3</xref>), but the number of subjects with MS reactivation, defined according to clinical or radiological parameters, was higher in the L-LY respect to the H-LY group (<italic>n</italic>=56, <italic>p</italic>=0.008, OR=5.80, 95% CI: 1.58–21.25), indicating that greater lymphocyte count during natalizumab therapy ensures the higher degree of protection from MS reactivation after its discontinuation (<xref ref-type="fig" rid="fig2-1352458512448106">Figure 2D</xref>). In line with this, the frequency of relapse-free subjects (81% versus 28%, <italic>n</italic>=56, <italic>p</italic>=0.0001, OR=11.55, 95% CI: 3.25–41.03) and the time to relapse (<italic>p</italic>&lt;0.0001, HR=0.19, 95% CI: 0.08–0.43) were higher in the H-LY group (<xref ref-type="fig" rid="fig2-1352458512448106">Figure 2E</xref>).</p>
<p>Furthermore, the mean number of T1 Gd+ lesions, T2 new/enlarging lesions and CALs observed at P6, was higher in the L-LY group (H-LY: <italic>n</italic>=24; L-LY: <italic>n</italic>=16; <italic>p</italic>&lt;0.05 for each parameter) (<xref ref-type="fig" rid="fig2-1352458512448106">Figure 2F</xref>). Only one case of rebound was recorded, and it was in the L-LY group (7 T1 Gd+ lesions, 8 T2 new/enlarging lesions).</p>
<p>Of note, the number of subjects whose lymphocytes went back to baseline values three months after the last natalizumab infusion was higher in the L-LY group (<italic>n</italic>=55, 71% versus 40% <italic>p</italic>=0.03). A positive correlation was found between the natalizumab-induced increase of lymphocytes at T6 and at P2 (<italic>n</italic>=55, <italic>r</italic>=0.38, <italic>p</italic>=0.004), indicating that lymphocytosis alone during natalizumab can predict disease reactivation after treatment discontinuation, as the degree of post-natalizumab lymphocytosis was related to lymphocytosis values during natalizumab.</p>
</sec>
<sec id="section16-1352458512448106">
<title>Akt regulates natalizumab-induced peripheral lymphocytosis</title>
<p>SNPs in the Akt gene can affect the function of its protein product and influence lymphocyte proliferation by modulating the apoptotic pathway.<sup><xref ref-type="bibr" rid="bibr18-1352458512448106">18</xref>,<xref ref-type="bibr" rid="bibr19-1352458512448106">19</xref>,<xref ref-type="bibr" rid="bibr21-1352458512448106">21</xref><xref ref-type="bibr" rid="bibr22-1352458512448106"/><xref ref-type="bibr" rid="bibr23-1352458512448106"/>–<xref ref-type="bibr" rid="bibr24-1352458512448106">24</xref></sup> Therefore, we tested the effect of six SNPs of the Akt gene on natalizumab-induced lymphocytosis. Variants of the six Akt SNPs failed to alter lymphocyte count before natalizumab initiation (<xref ref-type="table" rid="table4-1352458512448106">Table 4</xref>). One SNP of the Akt gene was instead associated with lymphocyte count alteration during natalizumab therapy, as patients carrying at least one rs2498804 T allele exhibited lower lymphocytosis (GG: <italic>n</italic>=29, GT/TT: <italic>n</italic>=38, <italic>p</italic>&lt;0.05 for each time point), and reduced probability of lymphocyte increase above 200% at T6 (<italic>n</italic>=67, <italic>p</italic>&lt;0.0001, OR=11.79, 95% CI: 3.72–37.38) (<xref ref-type="table" rid="table4-1352458512448106">Table 4</xref>; <xref ref-type="fig" rid="fig3-1352458512448106">Figure 3A</xref>).</p>
<table-wrap id="table4-1352458512448106" position="float">
<label>Table 4.</label>
<caption>
<p>Association between Akt single nucleotide polymorphisms (SNPs) and lymphocytosis.</p>
</caption>
<graphic alternate-form-of="table4-1352458512448106" xlink:href="10.1177_1352458512448106-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Akt SNPs</th>
<th align="left">T0 peripheral lymphocyte count (<italic>p</italic> value)</th>
<th align="left">T6 peripheral lymphocyte count (<italic>p</italic> value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs1130214</td>
<td>0.22</td>
<td>0.08</td>
</tr>
<tr>
<td>rs1130233</td>
<td>0.34</td>
<td>0.45</td>
</tr>
<tr>
<td>rs2494732</td>
<td>0.67</td>
<td>0.23</td>
</tr>
<tr>
<td>rs2498804</td>
<td>0.29</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>rs3730358</td>
<td>0.31</td>
<td>0.78</td>
</tr>
<tr>
<td>rs3803300</td>
<td>0.46</td>
<td>0.38</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig3-1352458512448106" position="float">
<label>Figure 3.</label>
<caption>
<p>rs2498804 SNP of Akt gene controls natalizumab-induced lymphocytosis and the risk of multiple sclerosis (MS) reactivation. (A) The natalizumab-induced lymphocytosis was higher in the GG than in the GT/TT group. (B) The graph shows that the difference in lymphocytosis values was caused by milder increase of CD4+ and CD8+ T lymphocytes in subjects carrying the T allele. (C) The number of subjects with MS reactivation was higher in GT/TT group with respect to GG group. (D) The relapse-free rate and the time to relapse were higher in GG group. (E) MRI parameters obtained from GG and GT/TT groups at P6.</p>
<p>MRI: magnetic resonance imaging; SNP: single nucleotide polymorphism.</p>
<p>*<italic>p</italic>&lt;0.05.</p>
</caption>
<graphic xlink:href="10.1177_1352458512448106-fig3.tif"/>
</fig>
<p>Counts of different cell populations demonstrated that the difference in lymphocytosis values was caused by the milder increase of CD4+ and CD8+ T lymphocytes in subjects carrying the rs2498804 T allele (GG: <italic>n</italic>=12, GT/TT: <italic>n</italic>=23, <italic>p</italic>&lt;0.05) (<xref ref-type="fig" rid="fig3-1352458512448106">Figure 3B</xref>).</p>
</sec>
<sec id="section17-1352458512448106">
<title>Akt controls the risk of MS reactivation after natalizumab</title>
<p>We next analyzed the association between Akt rs2498804 SNP and the occurrence of disease reactivation in a subgroup of subjects who discontinued natalizumab and consented to genetic analysis (<italic>n</italic>=42: 17 males, age 37.2±8.7 years).</p>
<p>At the suspension of natalizumab, the number of active subjects, defined according to clinical or radiological parameters, was higher in MS patients carrying at least one T allele (GT or TT) compared with the GG group (<italic>n</italic>=42, <italic>p</italic>=0.02, OR=5.28, 95% CI: 1.29–21.51) (<xref ref-type="fig" rid="fig3-1352458512448106">Figure 3C</xref>). Furthermore, the number of relapse-free subjects (79% versus 31%, <italic>n</italic>=42, <italic>p</italic>=0.003, OR=8.33, 95% CI: 2.15–32.31), and time to relapse (<italic>p</italic>=0.01, HR=0.29, 95% CI: 0.11–0.77) were higher in the GG group (<xref ref-type="fig" rid="fig3-1352458512448106">Figure 3D</xref>), and the mean number of T1 Gd+ lesions, T2 new/enlarging lesions and CALs observed at P6 were higher in the GT/TT group (GG: <italic>n</italic>=19; GT/TT: <italic>n</italic>=21, <italic>p</italic>&lt;0.05 for each parameter) (<xref ref-type="fig" rid="fig3-1352458512448106">Figure 3E</xref>).</p>
<p>No significant differences in demographic and clinical variables before natalizumab were found between GT/TT and GG subjects (<xref ref-type="table" rid="table5-1352458512448106">Table 5</xref>).</p>
<table-wrap id="table5-1352458512448106" position="float">
<label>Table 5.</label>
<caption>
<p>Demographic, clinical, and treatment information for GG and GT/TT patients.</p>
</caption>
<graphic alternate-form-of="table5-1352458512448106" xlink:href="10.1177_1352458512448106-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">GG</th>
<th align="left">GT/TT</th>
<th align="left"><italic>p</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject (<italic>n</italic>)</td>
<td>29</td>
<td>38</td>
<td/>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>9/20</td>
<td>16/22</td>
<td>0.45</td>
</tr>
<tr>
<td>Age (years)</td>
<td>37.1 ± 9.7</td>
<td>36.9 ± 7.3</td>
<td>0.94</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>8.4 ± 4.1</td>
<td>9.1 ± 3.8</td>
<td>0.43</td>
</tr>
<tr>
<td>ARR before natalizumab</td>
<td>2.4 ± 0.9</td>
<td>2.4 ± 0.9</td>
<td>0.91</td>
</tr>
<tr>
<td>Treatment before natalizumab therapy (IFNβ1b/IFNβ1a/GA/none)</td>
<td>10/8/8/3</td>
<td>9/14/12/3</td>
<td/>
</tr>
<tr>
<td>T0 EDSS</td>
<td>3.4 ± 1.1</td>
<td>3.1 ± 1.0</td>
<td>0.30</td>
</tr>
<tr>
<td>T0 peripheral lymphocytes (count/ml)</td>
<td>1881 ± 636</td>
<td>2113 ± 836</td>
<td>0.31</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1352458512448106">
<p>ARR: annualized relapse rate; EDSS: Expanded Disability Status Scale; F: female; GA: glatiramer acetate; IFN: interferon; M: male.</p>
</fn>
<fn id="table-fn8-1352458512448106">
<p>Data are mean ± standard deviation (SD) unless otherwise specified.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section18-1352458512448106">
<title>Discussion</title>
<p>The reason why natalizumab exposure may trigger reactivation of JC virus is unclear, but it has been suggested that this may be related to reduced immune surveillance within the CNS.<sup><xref ref-type="bibr" rid="bibr5-1352458512448106">5</xref>,<xref ref-type="bibr" rid="bibr33-1352458512448106">33</xref>,<xref ref-type="bibr" rid="bibr34-1352458512448106">34</xref></sup></p>
<p>Reactivation of MS was first reported in patients leaving the pivotal AFFIRM and SENTINEL trials of natalizumab, and many other case reports have since appeared.<sup><xref ref-type="bibr" rid="bibr9-1352458512448106">9</xref>,<xref ref-type="bibr" rid="bibr35-1352458512448106">35</xref></sup> An analysis of disease course following discontinuation of natalizumab in 1866 participants in the Phase III clinical development program for this drug has been recently published.<sup><xref ref-type="bibr" rid="bibr36-1352458512448106">36</xref></sup> This analysis demonstrated a consistent return of disease activity, in terms of relapses and new gadolinium-enhancing lesions, shortly after natalizumab interruption, and peaking between four and seven months. This recrudescence of disease was independent of overall natalizumab exposure, prior disease activity, concomitant or subsequent exposure to IFN-beta or GA.<sup><xref ref-type="bibr" rid="bibr36-1352458512448106">36</xref></sup></p>
<p>It appears that, in certain cases, the reactivated disease is even more aggressive than it was before natalizumab was started.<sup><xref ref-type="bibr" rid="bibr8-1352458512448106">8</xref></sup> This ‘rebound’ effect has been referred to as a CNS immune reconstitution syndrome (CIRIS), and it has been postulated that it arises due to the concerted wave of T and B cells re-entering the brain once the blood-brain barrier becomes permeable to immune cells, and the consequent synchronous reactivation of quiescent lesions.<sup><xref ref-type="bibr" rid="bibr37-1352458512448106">37</xref><xref ref-type="bibr" rid="bibr38-1352458512448106"/>–<xref ref-type="bibr" rid="bibr39-1352458512448106">39</xref></sup> Accordingly, natalizumab prevents penetration into the CNS of autoreactive B and T lymphocytes,<sup><xref ref-type="bibr" rid="bibr2-1352458512448106">2</xref></sup> and their abnormal survival in the periphery might, in principle, be involved in disease reoccurrence after natalizumab cessation. This view has been supported by the evidence that a therapeutic regimen with natalizumab induces an early and stable increase of circulating lymphocytes that generally reverts three to six months after the last infusion.<sup><xref ref-type="bibr" rid="bibr30-1352458512448106">30</xref><xref ref-type="bibr" rid="bibr31-1352458512448106"/>–<xref ref-type="bibr" rid="bibr32-1352458512448106">32</xref></sup></p>
<p>The mode of action of natalizumab is more complex than generally anticipated. Besides the well-known effect on cell trafficking, natalizumab reduces the expression of VLA-4 on T cells,<sup><xref ref-type="bibr" rid="bibr30-1352458512448106">30</xref></sup> impacting on long-term survival and cell activation.<sup><xref ref-type="bibr" rid="bibr40-1352458512448106">40</xref></sup> In addition, an effect of natalizumab on hematopoietic stem cell mobilization<sup><xref ref-type="bibr" rid="bibr41-1352458512448106">41</xref></sup> and gene expression has also been reported.<sup><xref ref-type="bibr" rid="bibr42-1352458512448106">42</xref></sup> Thus, the mechanism of natalizumab-induced lymphocyte increase could be due to a number of possibilities, including the modulation of apoptosis or differentiation processes.</p>
<p>Lymphocyte survival is regulated by complex mechanisms involving the apoptotic cascade and the DNA repair pathway.<sup><xref ref-type="bibr" rid="bibr15-1352458512448106">15</xref><xref ref-type="bibr" rid="bibr16-1352458512448106"/>–<xref ref-type="bibr" rid="bibr17-1352458512448106">17</xref>,<xref ref-type="bibr" rid="bibr20-1352458512448106">20</xref></sup> Our study describes the association between natalizumab-induced lymphocytosis, in particular T cell increase, and one SNP of the Akt gene with demonstrated biological effects.<sup><xref ref-type="bibr" rid="bibr19-1352458512448106">19</xref>,<xref ref-type="bibr" rid="bibr22-1352458512448106">22</xref>,<xref ref-type="bibr" rid="bibr23-1352458512448106">23</xref></sup></p>
<p>The serine–threonine kinase Akt is a central node in cell signaling that regulates several processes, including cell survival, proliferation, and protein synthesis.<sup><xref ref-type="bibr" rid="bibr21-1352458512448106">21</xref></sup> Akt activation is a common molecular alteration during carcinogenesis, and it has been reported that constitutive activation of Akt results in cell survival by blocking induction of apoptosis.<sup><xref ref-type="bibr" rid="bibr18-1352458512448106">18</xref>,<xref ref-type="bibr" rid="bibr24-1352458512448106">24</xref></sup> rs2498804 TT and GT variants of the Akt gene have already been found to impair Akt function, resulting in reduced cell survival and less aggressive cancer diseases.<sup><xref ref-type="bibr" rid="bibr23-1352458512448106">23</xref></sup> In agreement with this finding, we found that MS subjects carrying the same SNP variants develop less lymphocytosis during natalizumb, although baseline lymphocyte count was unaltered. These results, although preliminary, indicate that Akt has no role in determining lymphocyte survival and proliferation in basal condition, and that natalizumab could increase lymphocyte numbers by stimulating an anti-apoptotic pathway controlled by Akt. Further biochemical and immunological studies are needed to validate this hypothesis. Of note, the negative effect of natalizumab treatment on apoptosis might favor cell transformation and explain the association found between this treatment and lymphomas<sup><xref ref-type="bibr" rid="bibr43-1352458512448106">43</xref></sup> or melanomas.<sup><xref ref-type="bibr" rid="bibr44-1352458512448106">44</xref></sup></p>
<p>The results of the present investigation also indicate that the risk of MS reactivation after natalizumab discontinuation can be predicted on the basis of the effect of the treatment on lymphocyte count in peripheral blood. Somehow surprisingly, the data here presented suggest a protective rather than a detrimental role of natalizumab-induced lymphocytosis on post-natalizumab disease reactivation. In fact, a higher risk of a clinical relapse or of MRI reactivation was found after natalizumab cessation in those patients whose total lymphocyte count did not reach 200% of pre-treatment values after six months of treatment. Furthermore, we also found that although natalizumab increased the number of all lymphocyte cell lines, B lymphocytes preferentially increased over NK cells and T lymphocytes, this according with previous reports and in agreement with previous findings showing that VLA-4 expression is stronger on B cells than on T cells.<sup><xref ref-type="bibr" rid="bibr30-1352458512448106">30</xref></sup></p>
<p>It has been postulated that natalizumab-induced accumulation of T cells in peripheral blood may lead to MS exacerbation after discontinuation of the drug.<sup><xref ref-type="bibr" rid="bibr31-1352458512448106">31</xref></sup> Our data, however, support the opposite hypothesis, since the observed increase of CD4+ and CD8+ T cells during the treatment was associated in our sample with reduced risk of early disease reactivation after treatment cessation. Moreover, the association between the rs2498804 TT and GT variants of the Akt gene with the frequency of clinical and MRI evidence of disease reactivation strengthens the proposed relationship between circulating T cell increase during natalizumab treatment and the risk of MS exacerbation after stopping natalizumab.</p>
<p>In conclusion, the current study identified one functionally meaningful genetic variant within the Akt signaling pathway that is associated with both lymphocyte count and composition alterations during natalizumab treatment of MS patients and with the risk of disease reactivation after natalizumab discontinuation. Our findings may provide useful information for the stratification and individualized treatment of those MS patients who discontinue natalizumab to reduce the risk of severe side effects.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The present study was supported by a Fondazione Italiana Sclerosi Multipla (FISM, Progetto Speciale) grant to DC.</p>
</fn>
<fn fn-type="conflict">
<label>Declaration of conflicting interests</label>
<p>Silvia Rossi received honoraria for writing from Bayer Schering and funding for traveling from Novartis, Teva, Merck Serono. She is involved as sub-investigator in clinical trials for Novartis, Merck Serono, Teva, Bayer Schering, Sanofi-aventis, and Biogen Idec.</p>
<p>Valentina De Chiara received funding for traveling from Teva. She is involved as study coordinator in clinical trials for Novartis, Merck Serono, Teva, Bayer Schering, Sanofi-aventis, and Biogen Idec.</p>
<p>Giorgio Bernardi is the principal investigator in clinical trials for Merck Serono and Teva.</p>
<p>Gary Cutter was paid for consultancy from Antisense Therapeutics Limited (completed), Sanofi-Aventis, Bayhill Pharmaceuticals, BioMS Pharmaceuticals, Daichi-Sankyo, Genmab Biopharmaceuticals, Glaxo-Smith Kline, PTC Therapeutics, Medivation, EliLilly, Teva, Vivus, University of Penn, NHLBI, NINDS, NMSS, Ono Pharmaceuticals, Alexion Inc, Accentia (completed), Bayhill, Bayer, Barofold (completed), CibaVision (completed), Novartis, Diagenix (completed), Consortium of MS Centers (grant), Klein-Buendel Incorporated, Enzo Pharmaceuticals, Peptimmune, Somnus Pharmaceuticals, Teva Pharmaceuticals, UT-Southwestern, Visioneering Technologies, Sandoz; his institution had a grant given/pending to them by Variety via NARCOMS; was paid an honoraria from Biogen Idec, Consortium of MS Centers; was paid travel/accommodation expenses covered or reimbursed for DSMB meetings; owner of Pythagoras Incorporated, a Sub S corporation.</p>
<p>Olaf Stüve was paid for consultancy and received an honoraria from Teva Neuroscience, Roche, Genzyme, EMD-Serono, and Novartis.</p>
<p>Diego Centonze is an Advisory Board member of Merck-Serono, Teva, and Bayer Schering and received funding for traveling and honoraria for speaking or consultation fees from Merck Serono, Teva, Novartis, Bayer Schering, Sanofi-aventis, and Biogen Idec. He is also an external expert consultant of the European Medicine Agency (EMA) and the principal investigator in clinical trials for Novartis, Merck Serono, Teva, Bayer Schering, Sanofi-aventis, and Biogen Idec.</p>
<p>The other authors have no disclosures to report.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512448106">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Comi</surname><given-names>G</given-names></name>
</person-group>. <article-title>Treatment of multiple sclerosis: role of natalizumab</article-title>. <source>Neurol Sci</source> <year>2009</year>; <volume>30</volume>: <fpage>S155</fpage>–<lpage>S158</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512448106">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coyle</surname><given-names>PK</given-names></name>
</person-group>. <article-title>The role of natalizumab in the treatment of multiple sclerosis</article-title>. <source>Am J Manag Care</source> <year>2010</year>; <volume>16</volume>: <fpage>S164</fpage>–<lpage>S170</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512448106">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langer-Gould</surname><given-names>A</given-names></name>
<name><surname>Steinman</surname><given-names>L</given-names></name>
</person-group>. <article-title>Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab</article-title>. <source>Curr Neurol Neurosci Rep</source> <year>2006</year>; <volume>6</volume>: <fpage>253</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512448106">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindå</surname><given-names>H</given-names></name>
<name><surname>von Heijne</surname><given-names>A</given-names></name>
<name><surname>Major</surname><given-names>EO</given-names></name>
<etal/>
</person-group>. <article-title>Progressive multifocal leukoencephalopathy after natalizumab monotherapy</article-title>. <source>N Engl J Med</source> <year>2009</year>; <volume>361</volume>: <fpage>1081</fpage>–<lpage>1087</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512448106">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clifford</surname><given-names>DB</given-names></name>
<name><surname>De Luca</surname><given-names>A</given-names></name>
<name><surname>Simpson</surname><given-names>DM</given-names></name>
<etal/>
</person-group>. <article-title>Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases</article-title>. <source>Lancet Neurol</source> <year>2010</year>; <volume>9</volume>: <fpage>438</fpage>–<lpage>446</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512448106">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steiner</surname><given-names>I</given-names></name>
</person-group>. <article-title>PML: underdiagnosed in MS patients on natalizumab</article-title>. <source>Lancet Neurol</source> <year>2010</year>; <volume>9</volume>: <fpage>564</fpage>.</citation>
</ref>
<ref id="bibr7-1352458512448106">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorelik</surname><given-names>L</given-names></name>
<name><surname>Lerner</surname><given-names>M</given-names></name>
<name><surname>Bixler</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Anti-JC virus antibodies: implications for PML risk stratification</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>68</volume>: <fpage>295</fpage>–<lpage>303</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512448106">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fox</surname><given-names>RJ</given-names></name>
<name><surname>Kappos</surname><given-names>L</given-names></name>
</person-group>. <article-title>Is natalizumab overshooting its rebound?</article-title> <source>Neurology</source> <year>2008</year>; <volume>70</volume>: <fpage>1073</fpage>–<lpage>1074</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512448106">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vellinga</surname><given-names>MM</given-names></name>
<name><surname>Castelijns</surname><given-names>JA</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients</article-title>. <source>Neurology</source> <year>2008</year>; <volume>70</volume>: <fpage>1150</fpage>–<lpage>1151</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512448106">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berger</surname><given-names>JR</given-names></name>
<name><surname>Centonze</surname><given-names>D</given-names></name>
<name><surname>Comi</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Considerations on discontinuing natalizumab for the treatment of multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>68</volume>: <fpage>409</fpage>-<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512448106">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Killestein</surname><given-names>J</given-names></name>
<name><surname>Vennegoor</surname><given-names>A</given-names></name>
<name><surname>Strijbis</surname><given-names>EM</given-names></name>
<etal/>
</person-group>. <article-title>Natalizumab drug holiday in multiple sclerosis: poorly tolerated</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>68</volume>: <fpage>392</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512448106">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>West</surname><given-names>TW</given-names></name>
<name><surname>Cree</surname><given-names>BA</given-names></name>
</person-group>. <article-title>Natalizumab dosage suspension: are we helping or hurting?</article-title> <source>Ann Neurol</source> <year>2010</year>; <volume>68</volume>: <fpage>395</fpage>–<lpage>399</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512448106">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Havla</surname><given-names>J</given-names></name>
<name><surname>Gerdes</surname><given-names>LA</given-names></name>
<name><surname>Meinl</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate</article-title>. <source>J Neurol</source> <year>2011</year>; <volume>258</volume>: <fpage>1665</fpage>–<lpage>1669</lpage>.</citation>
</ref>
<ref id="bibr14-1352458512448106">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaufman</surname><given-names>MD</given-names></name>
<name><surname>Lee</surname><given-names>R</given-names></name>
<name><surname>Norton</surname><given-names>H</given-names></name>
</person-group>. <article-title>Course of relapsing-remitting multiple sclerosis before, during and after natalizumab</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>490</fpage>–<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr15-1352458512448106">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kroner</surname><given-names>A</given-names></name>
<name><surname>Mehling</surname><given-names>M</given-names></name>
<name><surname>Hemmer</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>A PD-1 polymorphism is associated with disease progression in multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2005</year>; <volume>58</volume>: <fpage>50</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr16-1352458512448106">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huck</surname><given-names>K</given-names></name>
<name><surname>Feyen</surname><given-names>O</given-names></name>
<name><surname>Niehues</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation</article-title>. <source>J Clin Invest</source> <year>2009</year>; <volume>119</volume>: <fpage>1350</fpage>–<lpage>1358</lpage>.</citation>
</ref>
<ref id="bibr17-1352458512448106">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morton</surname><given-names>LM</given-names></name>
<name><surname>Purdue</surname><given-names>MP</given-names></name>
<name><surname>Zheng</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <year>2009</year>; <volume>18</volume>: <fpage>1259</fpage>–<lpage>1270</lpage>.</citation>
</ref>
<ref id="bibr18-1352458512448106">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brognard</surname><given-names>J</given-names></name>
<name><surname>Clark</surname><given-names>AS</given-names></name>
<name><surname>Ni</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation</article-title>. <source>Cancer Res</source> <year>2001</year>; <volume>61</volume>: <fpage>3986</fpage>–<lpage>3997</lpage>.</citation>
</ref>
<ref id="bibr19-1352458512448106">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Emamian</surname><given-names>ES</given-names></name>
<name><surname>Hall</surname><given-names>D</given-names></name>
<name><surname>Birnbaum</surname><given-names>MJ</given-names></name>
<etal/>
</person-group>. <article-title>Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia</article-title>. <source>Nat Genet</source> <year>2004</year>; <volume>36</volume>: <fpage>131</fpage>–<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr20-1352458512448106">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shen</surname><given-names>M</given-names></name>
<name><surname>Lan</surname><given-names>Q</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Polymorphisms in genes involved in DNA double-strand break repair pathway and susceptibility to benzene-induced hematotoxicity</article-title>. <source>Carcinogenesis</source> <year>2006</year>; <volume>27</volume>: <fpage>2083</fpage>–<lpage>2089</lpage>.</citation>
</ref>
<ref id="bibr21-1352458512448106">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manning</surname><given-names>BD</given-names></name>
<name><surname>Cantley</surname><given-names>LC</given-names></name>
</person-group>. <article-title>AKT/PKB signaling: navigating downstream</article-title>. <source>Cell</source> <year>2007</year>; <volume>129</volume>: <fpage>1261</fpage>-<lpage>1274</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512448106">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hutz</surname><given-names>JE</given-names></name>
<name><surname>Manning</surname><given-names>WA</given-names></name>
<name><surname>Province</surname><given-names>MA</given-names></name>
<etal/>
</person-group>. <article-title>Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins</article-title>. <source>PLos One</source> <year>2011</year>; <volume>6</volume>: <fpage>e24873</fpage>.</citation>
</ref>
<ref id="bibr23-1352458512448106">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pu</surname><given-names>X</given-names></name>
<name><surname>Hildebrandt</surname><given-names>MA</given-names></name>
<name><surname>Lu</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy</article-title>. <source>Lung Cancer</source> <year>2011</year>; <volume>71</volume>: <fpage>82</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512448106">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schatz</surname><given-names>JH</given-names></name>
<name><surname>Wendel</surname><given-names>HG</given-names></name>
</person-group>. <article-title>Targeted cancer therapy: What if the driver is just a messenger?</article-title> <source>Cell Cycle</source> <year>2011</year>; <volume>10</volume>: <fpage>3830</fpage>–<lpage>3833</lpage>.</citation>
</ref>
<ref id="bibr25-1352458512448106">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
<name><surname>Edan</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’</article-title>. <source>Ann Neurol</source> <year>2005</year>; <volume>58</volume>: <fpage>840</fpage>–<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr26-1352458512448106">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurtzke</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)</article-title>. <source>Neurology</source> <year>1983</year>; <volume>33</volume>: <fpage>1444</fpage>–<lpage>1452</lpage>.</citation>
</ref>
<ref id="bibr27-1352458512448106">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jurinke</surname><given-names>C</given-names></name>
<name><surname>van den Boom</surname><given-names>D</given-names></name>
<name><surname>Cantor</surname><given-names>CR</given-names></name>
<etal/>
</person-group>. <article-title>The use of MassARRAY technology for high throughput genotyping</article-title>. <source>Adv Biochem Eng Biotechnol</source> <year>2002</year>; <volume>77</volume>: <fpage>57</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr28-1352458512448106">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hasan</surname><given-names>SK</given-names></name>
<name><surname>Buttari</surname><given-names>F</given-names></name>
<name><surname>Ottone</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>1059</fpage>–<lpage>1065</lpage>.</citation>
</ref>
<ref id="bibr29-1352458512448106">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mori</surname><given-names>F</given-names></name>
<name><surname>Ribolsi</surname><given-names>M</given-names></name>
<name><surname>Kusayanagi</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Genetic variants of the NMDA receptor influence cortical excitability and plasticity in humans</article-title>. <source>J Neurophysiol</source> <year>2011</year>; <volume>106</volume>: <fpage>1637</fpage>–<lpage>1643</lpage>.</citation>
</ref>
<ref id="bibr30-1352458512448106">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Putzki</surname><given-names>N</given-names></name>
<name><surname>Baranwald</surname><given-names>MK</given-names></name>
<name><surname>Tettenborn</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells</article-title>. <source>Eur Neurol</source> <year>2010</year>; <volume>63</volume>: <fpage>31</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr31-1352458512448106">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frisullo</surname><given-names>G</given-names></name>
<name><surname>Iorio</surname><given-names>R</given-names></name>
<name><surname>Plantone</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>556</fpage>–<lpage>566</lpage>.</citation>
</ref>
<ref id="bibr32-1352458512448106">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skarica</surname><given-names>M</given-names></name>
<name><surname>Eckstein</surname><given-names>C</given-names></name>
<name><surname>Whartenby</surname><given-names>KA</given-names></name>
<etal/>
</person-group>. <article-title>Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients</article-title>. <source>J Neuroimmunol</source> <year>2011</year>; <volume>235</volume>: <fpage>70</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr33-1352458512448106">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stüve</surname><given-names>O</given-names></name>
<name><surname>Marra</surname><given-names>CM</given-names></name>
<name><surname>Jerome</surname><given-names>KR</given-names></name>
<etal/>
</person-group>. <article-title>Immune surveillance in multiple sclerosis patients treated with natalizumab</article-title>. <source>Ann Neurol</source> <year>2006</year>; <volume>59</volume>: <fpage>743</fpage>–<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr34-1352458512448106">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stüve</surname><given-names>O</given-names></name>
<name><surname>Marra</surname><given-names>CM</given-names></name>
<name><surname>Bar-Or</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>2006</year>, <volume>63</volume>: <fpage>1383</fpage>–<lpage>1387</lpage>.</citation>
</ref>
<ref id="bibr35-1352458512448106">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schiess</surname><given-names>N</given-names></name>
<name><surname>Calabresi</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Natalizumab: bound to rebound?</article-title> <source>Neurology</source> <year>2009</year>; <volume>72</volume>: <fpage>392</fpage>–<lpage>393</lpage>.</citation>
</ref>
<ref id="bibr36-1352458512448106">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Connor</surname><given-names>PW</given-names></name>
<name><surname>Goodman</surname><given-names>A</given-names></name>
<name><surname>Kappos</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>1858</fpage>–<lpage>1865</lpage>.</citation>
</ref>
<ref id="bibr37-1352458512448106">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lenhard</surname><given-names>T</given-names></name>
<name><surname>Biller</surname><given-names>A</given-names></name>
<name><surname>Mueller</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?</article-title> <source>Neurology</source> <year>2010</year>; <volume>75</volume>: <fpage>831</fpage>–<lpage>833</lpage>.</citation>
</ref>
<ref id="bibr38-1352458512448106">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perumal</surname><given-names>J</given-names></name>
<name><surname>Caon</surname><given-names>C</given-names></name>
<name><surname>Hreha</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Post-natalizumab rebound: a CNS immune reconstitution syndrome (CIRIS)</article-title>. <source>Neurology</source> <year>2010</year>; <volume>74</volume>: <fpage>A558</fpage>.</citation>
</ref>
<ref id="bibr39-1352458512448106">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miravalle</surname><given-names>A</given-names></name>
<name><surname>Jensen</surname><given-names>R</given-names></name>
<name><surname>Kinkel</surname><given-names>RP</given-names></name>
</person-group>. <article-title>Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy</article-title>. <source>Arch Neurol</source> <year>2011</year>; <volume>68</volume>: <fpage>186</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr40-1352458512448106">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silvy</surname><given-names>A</given-names></name>
<name><surname>Altevogt</surname><given-names>P</given-names></name>
<name><surname>Mondiere</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>A role for the VLA-4 integrin in the activation of human memory B cells</article-title>. <source>Eur J Immunol</source> <year>1997</year>; <volume>27</volume>: <fpage>2757</fpage>–<lpage>2764</lpage>.</citation>
</ref>
<ref id="bibr41-1352458512448106">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neumann</surname><given-names>F</given-names></name>
<name><surname>Zohren</surname><given-names>F</given-names></name>
<name><surname>Haas</surname><given-names>R</given-names></name>
</person-group>. <article-title>The role of natalizumab in hematopoietic stem cell mobilization</article-title>. <source>Expert Opin Biol Ther</source> <year>2009</year>; <volume>9</volume>: <fpage>1099</fpage>–<lpage>1106</lpage>.</citation>
</ref>
<ref id="bibr42-1352458512448106">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindberg</surname><given-names>R</given-names></name>
<name><surname>Achtnichts</surname><given-names>L</given-names></name>
<name><surname>Hoffmann</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients</article-title>. <source>J Neuroimmunol</source> <year>2008</year>; <volume>194</volume>: <fpage>153</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr43-1352458512448106">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ransohoff</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum</article-title>. <source>Ann Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>259</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr44-1352458512448106">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>A</given-names></name>
<name><surname>Kemp</surname><given-names>J</given-names></name>
<name><surname>Sharrack</surname><given-names>B</given-names></name>
</person-group>. <article-title>Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis</article-title>. <source>J Neurol</source> <year>2009</year>; <volume>256</volume>: <fpage>1771</fpage>–<lpage>1772</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>